ATBECHDEDKESFRGBGRITLILUNLSEMCPTIESILTLVFIROMKCYALTRBGCZEEHUPLSK..HRIS..MTNORS..SM..................JBDM Ver 2.0.15 (20th of December) - 2999001/03575326CORRECTED EUROPEAN PATENT SPECIFICATIONB8B120220525W173deBibliographieenBibliographyfrBibliographieEP19185175.7201312172020060420201016enenen201261738008 P20121217US2022052520222120191204201949202204132022152021102720220525202221C07K 19/00 20060101AFI20210924BHEP A61K 38/16 20060101ALI20210924BHEP A61K 38/45 20060101ALI20210924BHEP A61P 35/02 20060101ALI20210924BHEP C07K 14/705 20060101ALI20210924BHEP C07K 16/00 20060101ALI20210924BHEP C12N 15/62 20060101ALI20210924BHEP A61K 38/00 20060101ALN20210924BHEP C07K2319/30 20130101 LA20140821BHEP A61K 38/00 20130101 LA20141020BHEP C07K 14/70503 20130101 FI20141217BHEP A61P 35/00 20180101 LI20200327BHEP A61P 35/02 20180101 LI20200327BHEP A61P 43/00 20180101 LI20200331BHEP deBEHANDLUNG VON CD47+-KRANKHEITSZELLEN MIT SIRP-ALPHA-FC-FUSIONENenTREATMENT OF CD47+ DISEASE CELLS WITH SIRP ALPHA-FC FUSIONSfrTRAITEMENT DE CELLULES TUMORALES À CD47+ AVEC DES FUSIONS SIRP ALPHA/FCWO-A1-2009/046541WO-A1-2010/130053A. NEIL BARCLAY ET AL: ") and CD47: Structure, Function, and Therapeutic Target", ANNUAL REVIEW OF IMMUNOLOGY, vol. 32, no. 1, 21 March 2014 (2014-03-21) , pages 25-50, XP055166307, ISSN: 0732-0582, DOI: 10.1146/annurev-immunol-032713-12014213865442.129317522013121722162692.220220317UGER, Robert Adam20 Reditt CourtRichmond Hill, Ontario L4C 7S4CASLAVOVA-PETROVA, Penka Slavtcheva1207-2261 Lake Shore Blvd WestToronto, Ontario M8V 3X1CAPANG, Xinli190 Mountainash RoadBrampton, Ontario L6R 3H1CATrillium Therapeutics ULC101941637P6120EP012488 Dunwin DriveMississauga, Ontario L5L 1J9CAScript IP Limited101333698Turnpike House 18 Bridge StreetFrome Somerset BA11 1BBGBALATBEBGCHCYCZDEDKEEESFIFRGBGRHRHUIEISITLILTLULVMCMKMTNLNOPLPTRORSSESISKSMTR